黑色素瘤的临床TIL经验：过去，现在，未来

IF 3.6 3区医学 Q2 HEMATOLOGY

Transplantation and Cellular Therapy Pub Date : 2025-03-01 DOI:10.1016/j.jtct.2024.11.013

James W. Smithy , Adam J. Schoenfeld , Allison Betof Warner

{"title":"黑色素瘤的临床TIL经验：过去，现在，未来","authors":"James W. Smithy , Adam J. Schoenfeld , Allison Betof Warner","doi":"10.1016/j.jtct.2024.11.013","DOIUrl":null,"url":null,"abstract":"<div><div>The recent approval of lifileucel by the US Food and Drug Administration in February 2024 was the culmination of over 3 decades of research in adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) for unresectable melanoma. In this review, we highlight key historical data for TIL therapy in melanoma as well as ongoing efforts to improve its efficacy and applicability.</div></div>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":"31 3","pages":"Pages S626-S634"},"PeriodicalIF":3.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Clinical TIL Experience in Melanoma: Past, Present, Future\",\"authors\":\"James W. Smithy , Adam J. Schoenfeld , Allison Betof Warner\",\"doi\":\"10.1016/j.jtct.2024.11.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The recent approval of lifileucel by the US Food and Drug Administration in February 2024 was the culmination of over 3 decades of research in adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) for unresectable melanoma. In this review, we highlight key historical data for TIL therapy in melanoma as well as ongoing efforts to improve its efficacy and applicability.</div></div>\",\"PeriodicalId\":23283,\"journal\":{\"name\":\"Transplantation and Cellular Therapy\",\"volume\":\"31 3\",\"pages\":\"Pages S626-S634\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transplantation and Cellular Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S266663672400784X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation and Cellular Therapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266663672400784X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

美国食品和药物管理局（fda）最近于2024年2月批准了lifileucel，这是30多年来肿瘤浸润淋巴细胞（til）过继细胞疗法治疗不可切除黑色素瘤研究的高潮。在这篇综述中，我们强调了TIL治疗黑色素瘤的关键历史数据，以及正在进行的提高其疗效和适用性的努力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Clinical TIL Experience in Melanoma: Past, Present, Future

The recent approval of lifileucel by the US Food and Drug Administration in February 2024 was the culmination of over 3 decades of research in adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) for unresectable melanoma. In this review, we highlight key historical data for TIL therapy in melanoma as well as ongoing efforts to improve its efficacy and applicability.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊